Epigenomics Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 63

Employees

  • Stock Symbol
  • ECX

Stock Symbol

  • Share Price
  • $1.20
  • (As of Friday Closing)

Epigenomics General Information

Description

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Contact Information

Website
epigenomics.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Bertha-Benz-Straße 5
  • 10557 Berlin
  • Germany
+49 030
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Stock Exchange
FRA
Vertical(s)
Industrials, Life Sciences, Oncology
Corporate Office
  • Bertha-Benz-Straße 5
  • 10557 Berlin
  • Germany
+49 030

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Epigenomics Stock Performance

As of 14-Feb-2025, Epigenomics’s stock price is $1.20. Its current market cap is $1.05M with 875K shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.20 $1.19 $0.54 - $2.40 $1.05M 875K 387.77

Epigenomics Financials Summary

As of 31-Dec-2023, Epigenomics has a trailing 12-month revenue of $5.46M.

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (1,723) (1,723) (7,137) (18,138)
Revenue 5,461 5,461 510 7,334
EBITDA (4,005) (4,005) (11,903) (2,307)
Net Income (12,642) (2,871)
Total Assets 14,198 14,198 17,000 27,924
Total Debt 0 0 902 521
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Epigenomics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Epigenomics‘s full profile, request access.

Request a free trial

Epigenomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic li
Diagnostic Equipment
Berlin, Germany
63 As of 2023

Irvine, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Epigenomics Competitors (41)

One of Epigenomics’s 41 competitors is Agendia, a Venture Capital-Backed company based in Irvine, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agendia Venture Capital-Backed Irvine, CA
Foundation Medicine Formerly VC-backed Cambridge, MA
Genomic Expression Venture Capital-Backed Beverly, MA
Illumina Formerly VC-backed San Diego, CA
Exact Sciences Formerly VC-backed Madison, WI
You’re viewing 5 of 41 competitors. Get the full list »

Epigenomics Patents

Epigenomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4185714-A1 Methods for detecting liver cancer Pending 21-Jul-2020
CA-3161720-A1 Methods for detecting colorectal cancer Pending 16-Dec-2019
EP-4077734-A1 Methods for detecting colorectal cancer Pending 16-Dec-2019
US-20200299779-A1 Methods for detecting head and neck cancer Inactive 13-Feb-2019
EP-3924737-A1 Methylated genomic dna as a marker of head and neck cancer Inactive 13-Feb-2019 C12Q1/6886
To view Epigenomics’s complete patent history, request access »

Epigenomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Epigenomics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Epigenomics’s complete esg history, request access »

Epigenomics FAQs

  • When was Epigenomics founded?

    Epigenomics was founded in 1998.

  • Where is Epigenomics headquartered?

    Epigenomics is headquartered in Berlin, Germany.

  • What is the size of Epigenomics?

    Epigenomics has 63 total employees.

  • What industry is Epigenomics in?

    Epigenomics’s primary industry is Diagnostic Equipment.

  • Is Epigenomics a private or public company?

    Epigenomics is a Public company.

  • What is Epigenomics’s stock symbol?

    The ticker symbol for Epigenomics is ECX.

  • What is the current stock price of Epigenomics?

    As of 14-Feb-2025 the stock price of Epigenomics is $1.20.

  • What is the current market cap of Epigenomics?

    The current market capitalization of Epigenomics is $1.05M.

  • What is Epigenomics’s current revenue?

    The trailing twelve month revenue for Epigenomics is $5.46M.

  • Who are Epigenomics’s competitors?

    Agendia, Foundation Medicine, Genomic Expression, Illumina, and Exact Sciences are some of the 41 competitors of Epigenomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »